ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Mar 3, 2025
FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase
FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit
Read more at globenewswire.com21.39
+1.75 (+8.91%)
Find more stocks in the Stock Screener
ADMA Latest News and Analysis
7 days ago - ChartmillInvestors seeking growth at a reasonable cost should explore ADMA BIOLOGICS INC (NASDAQ:ADMA).Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
